NeoProteomics is a provider of research services and tools that help clients unravel the complexities of pharmaceutical and biological research. Headquartered in Cleveland, Ohio, the company was founded by Dr. Mark Chance, Director of the Center for Proteomics and Bioinformatics at Case Western Reserve University (CWRU), John L. H. Schenkel, Jr. and Steven Chance in 2006, to evaluate and commercialize technologies developed at CWRU. NeoProteomics has licensed an attractive IP portfolio from CWRU, which serves as the foundation of cutting edge services that help researchers increase the speed and accuracy of their biologics and small molecular drug development. NeoProteomics currently provides expert services and tools to numerous partner companies and research laboratories worldwide.


Location: Northeast Ohio

Technology Sector: Medical

Funding Type: Series A